Progenics Pharmaceuticals Inc (PGNX)

5.85
NASDAQ : Health Care
Prev Close 5.81
Day Low/High 5.78 / 5.94
52 Wk Low/High 3.61 / 9.11
Avg Volume 1.38M
Exchange NASDAQ
Shares Outstanding 69.95M
Market Cap 406.39M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock

Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a "perilous reversal" (up big yesterday but down big today) candidate

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

The Dow Jones Industrial Average clocks its seventh straight record closing Wednesday amid better-than-expected earnings from Microsoft, the best performing stock in the blue-chip index.

These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?

These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?

Here's a look at how to trade some of the most active stocks on the market right now.

S&P 500, Dow on Track to Break Records as Microsoft Surges

S&P 500, Dow on Track to Break Records as Microsoft Surges

Stocks are at record intraday highs by mid-afternoon Wednesday as crude oil trades above $45 and positive quarterly results for Microsoft spread earnings season cheer.

Midday Report: Valeant Jumps on FDA Approval; Dow at Records

Midday Report: Valeant Jumps on FDA Approval; Dow at Records

Stocks moved higher, boosted by a series of earnings reports from the likes of Microsoft, Morgan Stanley and United Continental.

Progenics (PGNX) Stock Soars as Relistor Receives FDA Approval

Progenics (PGNX) Stock Soars as Relistor Receives FDA Approval

Progenics (PGNX) stock is spiking today after the FDA approved its Relistor treatment for constipation.

Stocks Move Higher as Crude Pares Losses

Stocks Move Higher as Crude Pares Losses

Stocks move higher on Wednesday after a weekly reading on crude oil inventories confirms declining supplies.

Dow on Track for Another Record Open as Microsoft Surges

Dow on Track for Another Record Open as Microsoft Surges

Stock futures climb on Wednesday as better-than-expected earnings from Microsoft push the stock higher in premarket trading.

Heavy Early Morning Activity On Progenics Pharmaceuticals (PGNX)

Heavy Early Morning Activity On Progenics Pharmaceuticals (PGNX)

Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a pre-market mover with heavy volume candidate

Futures Point Downward for U.S. Markets as Asia Opens Lower

Futures Point Downward for U.S. Markets as Asia Opens Lower

Investors are beginning to wonder if earnings season can support the latest records.

Valeant And Progenics Announce FDA Approves RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Valeant And Progenics Announce FDA Approves RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Sales of RELISTOR tablets are expected to commence in the Third Quarter 2016

Progenics Pharmaceuticals (PGNX) Stock: Weak On High Volume Today

Progenics Pharmaceuticals (PGNX) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a weak on high relative volume candidate

Interesting PGNX Put And Call Options For September 16th

Interesting PGNX Put And Call Options For September 16th

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading today, for the September 16th expiration.

5 Stocks I Like for 2016's Second Half

From Celgene to Ford, these names look promising.

Trade-Ideas: Progenics Pharmaceuticals (PGNX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Progenics Pharmaceuticals (PGNX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a strong on high relative volume candidate

3 Stocks on my Brexit Shopping List

Doing some incremental buying in names hit by the selloff with little U.K. exposure.

Noteworthy Monday Option Activity: PGNX, SIG, AMTG

Noteworthy Monday Option Activity: PGNX, SIG, AMTG

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Progenics Pharmaceuticals, Inc. , where a total of 6,097 contracts have traded so far, representing approximately 609,700 underlying shares.

First Week of February 2017 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week of February 2017 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.

Put Agenus, Progenics on Your Small-Cap List

Both have good capital appreciation potential.

Put Agenus, Progenics on Your Small-Cap List

Both have good capital appreciation potential.